Alcon, Inc. (NYSE: ACL) announced today that the U.S. Food and Drug Administration (FDA) has approved PATANASE (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE nasal spray, an extension to Alcon’s market-leading ocular allergy product line, will be available in [...]

Continue reading " Alcon’s PATANASE Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms "